{"title":"Progenitor cells and circulating endothelial cells are associated with disease activity and damage in systemic lupus erythematosus patients.","authors":"Gonzalo Silveira, Sabrina Ranero, Adriana Carlomagno, Andreina Brugnini, Natalia Trias, Daniela Lens, Martín Rebella, Álvaro Danza, Sofía Grille","doi":"10.1177/09612033251330124","DOIUrl":"10.1177/09612033251330124","url":null,"abstract":"<p><p>BackgroundDespite advancements in treatment, patients with Systemic Lupus Erythematosus (SLE) frequently experience disease flares, which contribute to organ damage and increase the risk of premature death. Assessing disease activity is essential for optimizing treatment and preventing further organ damage. This study aimed to investigate the relationship between levels of progenitor and circulating endothelial cells and SLE disease activity, as well as accumulated organ damage.MethodsWe conducted a case-control study measuring levels of CD34+CD45low/- progenitor cells, CD34+CD45low/-CD133+ progenitor cells, Endothelial Progenitor Cells (EPC), and Circulating Endothelial Cells (CEC) in peripheral blood using flow cytometry.ResultsThe study included 32 SLE patients and 28 matched controls. SLE patients exhibited significantly lower levels of CD34+CD45low/- progenitor cells (<i>p</i> = .001), CD34+CD45low/-CD133+ progenitor cells (<i>p</i> = .016), EPC (<i>p</i> = .018), and CEC (<i>p</i> < .001) compared to controls. Additionally, the cell subpopulations correlated with SLE activity biomarkers, with CD34+CD45low/- progenitor cells showing a moderate negative correlation with C3 and C4 levels. Notably, patients with an SDI score ≥1 had significantly higher levels of CD34+CD45low/- progenitor cells, CD34+CD45low/- CD133+ progenitor cells, EPC, and CEC compared to those without organ damage (<i>p</i> = .0073, <i>p</i> = .018, <i>p</i> = .018, and <i>p</i> = .020, respectively).ConclusionOur findings reveal that CD34+CD45low/- progenitor cells, CD34+CD45low/-CD133+ progenitor cells, EPC, and CEC are significantly reduced in SLE patients and are associated with disease activity and organ damage. These results suggest that CD34+CD45low/- progenitor cells, in particular, could serve as potential biomarkers for monitoring disease activity and organ damage in SLE patients. Prospective studies are warranted to confirm these findings.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"551-561"},"PeriodicalIF":1.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143700792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Reversible lymphoproliferative disorder in systemic lupus erythematosus treated with mycophenolate mofetil: A case report and literature review.","authors":"Hiroto Tomoda, Muneo Nakaya, Seiichiro Nakabeppu, Hiroaki Miyoshi, Koichi Ohshima, Yuji Miyoshi","doi":"10.1177/09612033251330101","DOIUrl":"10.1177/09612033251330101","url":null,"abstract":"<p><p>BackgroundMycophenolate mofetil (MMF) is widely used to treat systemic lupus erythematosus (SLE), particularly in cases with severe and organ-threatening complications such as lupus nephritis. However, multiple reports have documented lymphoproliferative disorder (LPD) in patients with SLE undergoing MMF therapy, predominantly developing in the central nervous system and requiring aggressive treatment, including chemotherapy, radiation, and surgery.Case ReportWe herein report the case of a 58-year-old female patient with SLE who developed cervical, hepatic hilar, and para-aortic lymphadenopathy 8 years after initiating MMF treatment. Histopathological examination of the left cervical lymph node revealed features consistent with polymorphic LPD. MMF was discontinued, and after 2 months of surveillance, the enlarged lymph nodes regressed without need for additional treatment.ConclusionTo the best of our knowledge, this is the first reported case of MMF-associated LPD occurring outside the central nervous system in a patient with SLE, which resolved spontaneously upon MMF withdrawal. Clinicians should remain vigilant regarding the possibility of MMF-associated LPD when administering MMF to patients with SLE.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"633-639"},"PeriodicalIF":1.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143729521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
LupusPub Date : 2025-05-01Epub Date: 2025-04-01DOI: 10.1177/09612033251332051
Nooshin Hemmati, Maryam Sahebari, Mona Larki, Vahid Ghavami, Elham Manouchehri
{"title":"Investigating the association between antiphospholipid syndrome and ovarian reserve: A systematic review and meta-analysis of the literature.","authors":"Nooshin Hemmati, Maryam Sahebari, Mona Larki, Vahid Ghavami, Elham Manouchehri","doi":"10.1177/09612033251332051","DOIUrl":"10.1177/09612033251332051","url":null,"abstract":"<p><p>BackgroundAutoimmune diseases can reduce ovarian reserves. Women in reproductive ages are susceptible to an autoimmune disorder known as antiphospholipid syndrome (APS). The aim of this study is to investigate the association between APS and ovarian reserve (OR).MethodPubMed, Scopus, Web-of-Science, Science Direct, and the Google scholar search engine were searched (22 June 2024) for studies that investigated the effect of APS on OR. Literature screening, data extraction, and assessment of the risk of bias of the included studies were conducted by two reviewers independently. Mean differences were computed using a random effects model. Heterogeneity was assessed by I<sup>2</sup>%.ResultsFour cross-sectional studies were included in this meta-analysis. None of the studies had a high risk of bias. There was no significant association identified between primary (MD = -0.27, 95% CI, -1.42 to 0.87, <i>p</i> = 0.639) and secondary APS (SMD = -0.38, 95% CI, -2.46 to 1.69, <i>p</i> = 0.717) with antimullerian hormone amounts. The antral follicle count (AFC) was investigated in two studies revealed lower levels of AFC in women with primary APS. Regarding the levels of gonadotropins and estradiol in the participants' serum, the results are contradictory.ConclusionsThe results of this meta-analysis identified there is no relationship between primary and secondary APS with the reduction of ovarian reserves in women with APS. This issue should be considered in the reproductive health of women with APS, who can have children at the right time by consulting a rheumatologist and reproductive health specialist.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"588-596"},"PeriodicalIF":1.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143753340","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Skin and beyond: Demographics, clinical features and systemic involvement of cutaneous lupus erythematosus in Pakistani population.","authors":"Misbah Zakir Abowath, Erum Ashraf, Umair Zakir Abowath","doi":"10.1177/09612033251330115","DOIUrl":"10.1177/09612033251330115","url":null,"abstract":"<p><p>BackgroundLupus erythematosus (LE) is an autoimmune disease with skin being the most important organ involved and presents as LE specific and LE nonspecific lesions.ObjectiveTo determine the clinical demographics, systemic involvement and disease impact on daily lives of patients of cutaneous lupus erythematosus (CLE).MethodologyA cross sectional study of a total of 135 patients who presented with cutaneous symptoms were enrolled. Informed consent was taken. Detailed History, examination, clinical features, laboratory and radiograph investigations were conducted to assess the systemic involvement of internal organs.ResultsOf the 135 patients, 73.3% patients were female and 26.7% were male. Mean age was 28.1 years and duration of CLE was 8.4 months. 56.3% of patients belonged to the rural area. Isolated Chronic CLE (CCLE) was observed in 35.5%, CCLE with overlap Acute CLE (ACLE) in 30.3% and Isolated ACLE in 33.3%. Only two patients had Sub acute CLE (SCLE). In LE specific lesions, limited and generalized discoid rash was noted in 33.3% and 17.7% respectively. 46.6% patients had Malar rash. Oral and nasal ulcers were observed in 51.1 %. Non scarring alopecia was seen in 53.3% of patients. Scarring alopecia was observed in 35.5%. 34% patients had Raynaud's phenomenon, 23.7% had Periungual telangiectasia, and 14.8% had Vasculitis. In systemic involvement, joint involvement was observed in 49 patients (36.3%), renal in 48 patients (35.6%), haematological in 42 patients (31.1%), serositis, 23 patients (17%) and neurological in 14 patients (10.4%). No difference in sexes was observed. ANA positivity was seen in 61 patients, (45.1%), most of whom were females. (56.5%) Anti DSDNA was positive in 42 patients (31.1%) of which 40 were women. Mean DLQI was 11.01 ± 8.2. 45 patients had no or slight effect on their lives. 22.9%, 27.4% and 16.3% had moderate, large and very large effects of CLE on their lifestyle.ConclusionThe clinical characteristics of cutaneous lupus is similar to other studies, but the renal involvement is higher with cutaneous involvement in this study, while Serositis is less prevalent. Localized discoid lupus did not show extra cutaneous involvement, but showed significant impact on daily life.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"640-647"},"PeriodicalIF":1.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143729914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Implications of serum calcitonin gene-related peptide and type I interferon in systemic lupus erythematosus-associated headaches.","authors":"Shu Sugimoto, Yasuhiro Shimojima, Dai Kishida, Takanori Ichikawa, Ryota Takamatsu, Nobuyuki Yajima, Kunihiro Ichinose, Toshimasa Shimizu, Ryusuke Yoshimi, Takashi Kida, Takayuki Katsuyama, Yusuke Matsuo, Hiroshi Kajiyama, Ayuko Takatani, Yoshiki Sekijima","doi":"10.1177/09612033251332789","DOIUrl":"10.1177/09612033251332789","url":null,"abstract":"<p><p>ObjectiveHeadache is a common neurological symptom in patients with systemic lupus erythematosus (SLE). Calcitonin gene-related peptide (CGRP) is a potential chemical mediator of headaches, while type I interferon (IFN) plays a pivotal role in the immune system of SLE. This study investigated the implications of CGRP and type I IFNs as headache biomarkers in patients with SLE.MethodsWe used clinical information and serum samples from 144 patients with SLE from a Japanese multicenter cohort and a biobank. Serum CGRP, IFN-α, and IFN-β levels, which were measured using enzyme-linked immunoassay, were compared among patients with headache, those without headache, and 20 healthy controls (HC). These levels were compared based on the severity of daily disability caused by headaches as determined using the Migraine Disability Assessment.ResultsOf the 144 patients, 60 had headache (median age, 42 years; 56 women) and were significantly younger than patients without headache (median age, 49 years; 77 women) (<i>p</i> < .005). Both groups had a median SLE Disease Activity Index 2000 score of 4.0, which was not significantly different, whereas photosensitivity was significantly more prevalent in patients with headache than in those without headache (<i>p</i> < .05). Serum CGRP and IFN-α levels were not significantly different between patients with headache, those without headache, and HC. Serum IFN-β levels were significantly higher in patients with headache than in those without headache (<i>p</i> < .005), while being significantly lower in both patients with and without headache than in HC (<i>p</i> < .005). No significant differences in serum CGRP, IFN-α and IFN-β levels were observed based on the severity of daily disability related to headaches.ConclusionSerum CGRP and type I IFNs levels may not be involved in SLE-associated headaches.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"608-616"},"PeriodicalIF":1.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143780409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
LupusPub Date : 2025-05-01Epub Date: 2025-04-20DOI: 10.1177/09612033251332052
Jing Zhang, Yue Sun, Na Zhang, Li-Hua Chang, Lei Jin, Yun Guo
{"title":"Efficacy and safety of telitacicept in the treatment of systemic lupus erythematosus: A retrospective real-world study.","authors":"Jing Zhang, Yue Sun, Na Zhang, Li-Hua Chang, Lei Jin, Yun Guo","doi":"10.1177/09612033251332052","DOIUrl":"https://doi.org/10.1177/09612033251332052","url":null,"abstract":"<p><p>ObjectivesTo assess the real-world efficacy and safety of telitacicept in Chinese systemic lupus erythematosus (SLE) patients.MethodsThis retrospective single-center observational study enrolled 41 SLE patients treated with telitacicept between April 2021 and March 2022. Baseline characteristics and 24-week follow-up clinical outcomes were collected for analysis.ResultsA total of 41 SLE patients who received telitacicept at least once were included. Compared with baseline (10.0 ± 6.85), SLEDAI-2K scores significantly decreased at 12 weeks (6.25 ± 5.46, <i>p</i> < .001) and 24 weeks (4.18 ± 4.78, <i>p</i> < .001). The proportion of organ involvement, as assessed by SLEDAI-2K, significantly decreased in skin/mucosa and musculoskeletal involvement. The mean glucocorticoid dose (prednisone equivalent) was significantly reduced at 12 weeks (14.19 ± 8.88 mg/d, <i>p</i> < .001) and 24 weeks (9.86 ± 4.25 mg/d, <i>p</i> = .001) compared with baseline (20.87 ± 16.71 mg/d). C3 and C4 levels showed an increasing trend. In patients with lupus nephritis, 24-h urinary protein levels significantly reduced from 2.81 ± 3.83 g/day at baseline to 1.00 ± 1.32 g/day after 24 weeks of treatment (<i>p</i> = .005), with a 68.66% decline (IQR, 35.61%, 76.30%). Albumin levels also significantly improved (<i>p</i> = .003). Nine treatment-emergent adverse events (TEAEs) were recorded in six patients, all of which were mild and moderate.ConclusionsIn this real-world study, telitacicept combined with conventional therapy showed good onset efficacy and safety for treating SLE patients.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":"34 6","pages":"597-607"},"PeriodicalIF":1.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12010050/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143989309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
LupusPub Date : 2025-05-01Epub Date: 2025-04-20DOI: 10.1177/09612033251332054
Sarah B Lieber, Yvonne M Shea, Deanna Jannat-Khah, John A Carrino, M Carrington Reid, Lisa A Mandl
{"title":"Association of a self-report screening tool for sarcopenia (SARC-F) with functional status outcomes in systemic lupus erythematosus.","authors":"Sarah B Lieber, Yvonne M Shea, Deanna Jannat-Khah, John A Carrino, M Carrington Reid, Lisa A Mandl","doi":"10.1177/09612033251332054","DOIUrl":"10.1177/09612033251332054","url":null,"abstract":"<p><p>Background/PurposeSarcopenia, i.e., loss of skeletal muscle mass and strength, is associated with poorer health. Although limited data suggest that sarcopenia is more prevalent among adults with (vs without) systemic lupus erythematosus (SLE), current methods for assessing sarcopenia are cumbersome and not widely available. We assessed associations of a self-report screening tool for sarcopenia (SARC-F) with functional outcomes in adults with SLE.MethodsWe obtained self-report functional measures and performance-based measures of physical function from women ≥18 years of age with SLE. Participants completed the SARC-F, covering strength, assistance walking, rising from a chair, climbing stairs, and falls. We compared self-report functional measures and performance-based measures of physical function between dichotomized SARC-F scores (≥4 vs <4). We used Pearson correlations and linear and logistic regression to evaluate the relationship between the SARC-F as a continuous and dichotomous score with self-report functional measures and performance-based measures of physical function.ResultsOf 47 participants, 16 (34%) had worse SARC-F scores (i.e., ≥4). Participants with SARC-F ≥4 had worse organ damage and functional measures than those with SARC-F <4 (all <i>p</i> < 0.01). SARC-F continuous scores were correlated with hand grip strength, 4-m walk test, and self-report disability (all <i>p</i> < 0.01) and associated with functional status measures, including after adjustment (<i>p</i> < 0.01 to <i>p</i> = 0.046). Dichotomous SARC-F was associated with 4-m walk test (<i>p</i> < 0.01), including in adjusted models.ConclusionAmong women with SLE, SARC-F was significantly associated with multiple functional status measures, suggesting that SARC-F is a promising screening tool for detection of sarcopenia among women with SLE.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":"34 6","pages":"626-632"},"PeriodicalIF":1.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12097523/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143989857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Significant association of functional variants in the promoter sequence of <i>IL18</i> with disease susceptibility and systemic lupus erythematosus clinical parameters.","authors":"Yousef Mohammadi, Mozhdeh Saghaei, Mostafa Saghi, Seyed Amirhosein Mazhari, Behrang Alani, Naeim Ehtesham, Taiebe Kenarangi, Mohsen Soosanabadi","doi":"10.1177/09612033251331256","DOIUrl":"10.1177/09612033251331256","url":null,"abstract":"<p><p>ObjectiveSystemic lupus erythematosus (SLE) is a chronic autoimmune disease with a complex etiology. Interleukin-18 (IL-18) possesses pro-inflammatory properties and plays a central role in the development of SLE. In this study, we assessed the association between two functional variants that affect the expression of <i>IL-18</i>, namely -607C > A (rs1946518) and -137G > C (rs187238), and the risk of SLE development.MethodsAs a case-control study, 251 peripheral blood samples were collected from 121 SLE patients and 130 healthy participants. Genotyping of these polymorphisms was performed using the high-resolution melting (HRM) method, which employs real-time polymerase chain reaction.ResultsOur findings revealed a significant association between the AA genotype and A allele in rs1946518, showing a decreased risk of SLE (AA vs CC; OR: 0.386; 95% CI [0.174-0.828], A vs C; OR: 0.548; 95% CI [0.369-0.809]). Analogously, the CC genotype and C allele in rs187238 exhibited a similar trend (CC vs GG; OR: 0.240; 95% CI [0.055-0.803], C vs G; OR: 0.604; 95% CI [0.390-0.928]), indicating a reduced risk of SLE Moreover, SLE subjects with the protective allele in rs1946518 (AA + AC) demonstrated significantly lower levels of CRP, and Anti-dsDNA, suggesting lower disease activity. These patients also had a later age of onset, and a lower incidence of renal involvement and creatinine levels, indicating milder disease severity (<i>p</i> < <i>.05</i>).ConclusionThe study indicates a significant relationship between the rs1946518 and rs187238 variants in <i>IL-18</i> and a reduced risk of SLE. Furthermore, rs1946518 was found to be associated with certain clinical features related to disease activity and severity.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"579-587"},"PeriodicalIF":1.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143743618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Disease exacerbation and COVID-19 following mRNA COVID-19 vaccination in adolescents with Systemic Lupus Erythematosus.","authors":"Sutheera Thepveera, Sirirat Charuvanij, Maynart Sukharomana, Yanarin Thunsiribuddhichai, Kraisoon Lomjansook, Thanaporn Chaiyapak, Anirut Pattaragarn, Achra Sumboonnanoda, Nuntawan Piyaphanee","doi":"10.1177/09612033251331244","DOIUrl":"10.1177/09612033251331244","url":null,"abstract":"<p><p>ObjectivesTo evaluate disease flares and associated factors, as well as the Coronavirus disease 2019 (COVID-19) among adolescents with systemic lupus erythematosus (SLE) after receiving COVID-19 vaccination. Additionally, it sought to determine any difference in year-on-year flare rates before and after vaccination.MethodsWe conducted a 12-month prospective study in adolescent SLE (adoSLE) patients aged 12-18 years who had no prior history of COVID-19 and received a 2-dose BNT162b2 mRNA COVID-19 vaccine. A booster dose was administered 4-6 months later, depending on vaccine availability and patient acceptance. Clinical characteristics, the safety of estrogens in lupus erythematosus national assessment-SLE disease activity index (SELENA-SLEDAI) flare index, and renal flare were evaluated and contrasted against pre-vaccination data. COVID-19 during follow-up were noted.ResultsSixty-nine vaccinated adoSLE patients, with the mean age of 15.8 ± 1.6 years and female predominant (92.8%), were included. Forty-six (66.7%) patients received a booster dose at 4-6 months after primary series. Compared between pre- and post- COVID-19 vaccination, year-on-year flare rates remained consistent [20 (29.0%) versus 24 (34.8%), <i>p</i> = .371]. Non-use of hydroxychloroquine (adjusted odds ratio [aOR] 18.83, 95% CI: 1.97, 179.60, <i>p</i> = .011) and a SELENA-SLEDAI score ≥8 within 12 months prior to vaccination (aOR 5.33, 95% CI: 1.38, 20.55, <i>p</i> = .015) were independent factors of disease flares. An increment in post-vaccine renal flare rate was observed [6 (8.7%) versus 14 (20.3%), <i>p</i> = .046]. Among 14 adoSLE patients with renal flare, 13 (92.9%) patients had previous lupus nephritis, and new-onset proteinuria or increased proteinuria (71.4%) was the most common finding. Thirty-four (49.3%) patients contracted COVID-19 within a year post-vaccination, all presenting with mild to moderate symptoms; among the 46 patients who received a booter, 15 (32.6%) experienced COVID-19.ConclusionsCOVID-19 vaccination is effective and safe in preventing severe COVID-19 among adoSLE patients, without increasing annual SLE flare rates. However, close monitoring for renal flares is recommended, particularly for patients with a history of LN. Although vaccinated adoSLE patients contracted COVID-19, their outcomes were favorable.</p>","PeriodicalId":18044,"journal":{"name":"Lupus","volume":" ","pages":"562-570"},"PeriodicalIF":1.9,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143743616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}